Non-hormonal therapies for hormone-refractory prostate cancer
Author Information
Author(s): Eric Winquist, Tricia Waldron, Scott Berry, D Scott Ernst, Sébastien Hotte, Himu Lukka
Primary Institution: Cancer Care Ontario Program in Evidence-based Care
Hypothesis
Which non-hormonal systemic therapies are most beneficial for the treatment of men with hormone-refractory prostate cancer and clinical evidence of metastases?
Conclusion
Docetaxel-based chemotherapy modestly improves survival and provides palliation for men with hormone-refractory prostate cancer and metastases.
Supporting Evidence
- Docetaxel-based chemotherapy improved overall survival compared to mitoxantrone-prednisone.
- Improved progression-free survival and rates of palliative response were observed with docetaxel.
- Mitoxantrone plus corticosteroid showed improved disease control compared to corticosteroid alone.
Takeaway
This study looked at different treatments for men with prostate cancer that doesn't respond to hormone therapy. It found that one type of chemotherapy can help them live longer and feel better.
Methodology
A systematic review was performed to identify RCTs or meta-analyses examining first-line non-hormonal systemic therapy in patients with HRPC and metastases.
Potential Biases
The review may be subject to publication bias as smaller trials with negative results are less likely to be published.
Limitations
The review included only trials with a minimum sample size of 50 patients per arm, potentially excluding smaller but relevant studies.
Participant Demographics
The study included 7489 men with hormone-refractory prostate cancer and metastases.
Statistical Information
P-Value
p = 0.009
Confidence Interval
95% CI, 0.62–0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website